US2024025919A1PendingUtilityA1
Aza-tetracyclic oxazepine compounds and uses thereof
Est. expiryMay 19, 2042(~15.8 yrs left)· nominal 20-yr term from priority
Inventors:Matthew Leo LandryChristian NilewskiMichael SiuElisia VillemureYong WangBinqing WeiMelissa Ann AshleySteven DoLewis GazzardSamantha Alyson Green
A61P 35/04A61P 35/00A61K 31/553C07D 498/22A61K 45/06C07D 519/00
72
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Provided herein are aza-tetracyclic oxazepinyl compounds useful in the treatment of cancers.
Claims
exact text as granted — not AI-modified1 . A compound of formula (I):
or a stereoisomer, atropisomer, tautomer, or pharmaceutically acceptable salt thereof,
wherein
X is O or NR 6 ;
m is 1 or 2;
n is 1 or 2;
wherein n and m together make a 6—or 7-membered ring Ring A;
p is 0, 1, or 2,
R 1 is formula
wherein X 1 is N or CR 7C and R 7C is hydrogen or halogen;
each R 7A is independently halogen, CN, NH 2 , N(Me) 2 , R 7B -substituted or unsubstituted C 1-3 alkyl, unsubstituted C 1-3 haloalkyl, or unsubstituted cyclopropyl;
R 7B is CN, oxo, or C 1-3 alkyl;
L 1 is R L1 -substituted or unsubstituted C 1-4 alkylene;
R L1 is halogen or unsubstituted C 1-3 alkyl, or wherein two R L1 together form an unsubstituted C3.4 cycloalkyl;
R 2 is R 9 -substituted or unsubstituted 4-10 membered heterocycle comprising one or more heteroatoms selected from N, S, or O;
R 9 is independently halogen, CN, OH, OCF 3 , OCHF 2 , OCH 2 F, R 10 -substituted or unsubstituted C 1-3 alkyl, R 10 -substituted or unsubstituted C 1-3 haloalkyl, unsubstituted C 1-3 alkoxy, R 10 -substituted or unsubstituted C 1-3 alkylidene, or R 10 -substituted or unsubstituted C 3 0.4 cycloalkyl, or R 10 -substituted or unsubstituted 3 or 4-membered heterocycle; or wherein two R 9 together form a R 10 -substituted or unsubstituted C 3-5 cycloalkyl or a R 10 -substituted or unsubstituted C 3-5 heterocycle comprising one or more oxygen atoms; or wherein two R 9 together form a bridge between two carbon atoms of the cycloalkyl or heterocycle, wherein the bridge comprises 1-3 carbons;
each R 10 is independently hydrogen, oxo, CN, halogen, or C 1-3 unsubstituted alkyl;
R 3 is hydrogen, —CN, halogen, unsubstituted C 1-3 alkyl, or unsubstituted cyclopropyl;
each R 4 is independently hydrogen, methyl, or C 1-3 haloalkyl;
R 5 is independently halogen, oxo, unsubstituted C 1-3 alkyl, or unsubstituted C 1-3 haloalkyl;
or wherein two R 5 together form a bridge between two carbon atoms of Ring A, wherein the bridge comprises 1-3 carbons and optionally one heteroatom selected from O and N; or
two R 5 together form a bridge between two carbon atoms of Ring A, wherein the bridge comprises one of O or NR 11 ;
R 11 is hydrogen, C(O)CH 3 , or unsubstituted C 1-3 alkyl;
R 6 is hydrogen, R 6A -substituted or unsubstituted C 1 -6 alkyl, R 6A -substituted or unsubstituted C 1 -s haloalkyl, R 6A -substituted or unsubstituted C 1 -6 alkenyl; R 6A -substituted or unsubstituted C 1-6 alkynyl, or R 6A -substituted or unsubstituted 3-4 membered heterocycle;
R 6A is halogen, CN, OR 6B , SR 6C , S(O) 2 R 6C , C(O)R 6B , unsubstituted C 1-3 alkyl, unsubstituted C 1-3 haloalkyl, or R 6B -substituted or unsubstituted 3-4 membered heterocycle; and
R 6B and R 6C are each independently C 1-3 alkyl or C 1-3 haloalkyl.
2 - 3 . (canceled)
4 . A compound of formula (I):
or a stereoisomer, atropisomer, tautomer, or pharmaceutically acceptable salt thereof,
wherein
X is O or NR 6 ;
m is 1 or 2;
n is 1 or 2;
wherein n and m together make a 6— or 7-membered ring Ring A;
p is 0, 1, or 2;
R 1 is (E2) or (E3)
each R 7A is independently hydrogen, halogen, unsubstituted C 1-3 alkyl or unsubstituted C 1-3 haloalkyl;
L 1 is R L1 -substituted or unsubstituted C 1-4 alkylene;
R L1 is halogen or unsubstituted C 1-3 alkyl, or wherein two R L1 together form an unsubstituted C3.4 cycloalkyl;
R 2 is R 9 -substituted or unsubstituted 4-10 membered heterocycle comprising one or more heteroatoms selected from N, S, or O;
R 9 is independently halogen, CN, OH, OCF 3 , OCHF 2 , OCH 2 F, R 10 -substituted or unsubstituted C 1-3 alkyl, R 10 -substituted or unsubstituted C 1-3 haloalkyl, unsubstituted C 1-3 alkoxy, R 10 -substituted or unsubstituted C 1-3 alkylidene, or R 10 -substituted or unsubstituted C 3-4 cycloalkyl, or R 10 -substituted or unsubstituted 3 or 4-membered heterocycle; or wherein two R 9 together form a R 10 -substituted or unsubstituted C 3-5 cycloalkyl or a R 10 -substituted or unsubstituted C 3-5 heterocycle comprising one or more oxygen atoms; or wherein two R 9 together form a bridge between two carbon atoms of the cycloalkyl or heterocycle, wherein the bridge comprises 1-3 carbons;
each R 10 is independently hydrogen, oxo, CN, halogen, or C 1-3 unsubstituted alkyl;
R 3 is hydrogen, —CN, halogen, unsubstituted C 1-3 alkyl, or unsubstituted cyclopropyl;
each R 4 is independently hydrogen, methyl, or C 1-3 haloalkyl;
R 5 is independently halogen, oxo, unsubstituted C 1-3 alkyl, or unsubstituted C 1-3 haloalkyl;
or wherein two R 5 together form a bridge between two carbon atoms of Ring A, wherein the bridge comprises 1-3 carbons and optionally one heteroatom selected from O and N; or
two R 5 together form a bridge between two carbon atoms of Ring A, wherein the bridge comprises one of O or NR 11 ;
R 11 is hydrogen, C(O)CH 3 , or unsubstituted C 1-3 alkyl;
R 6 is hydrogen, R 6A -substituted or unsubstituted C 1 -6 alkyl, R 6A -substituted or unsubstituted C 1 -s haloalkyl, R 6A -substituted or unsubstituted C 1 -6 alkenyl; R 6A -substituted or unsubstituted C 1-6 alkynyl, or R 6A -substituted or unsubstituted 3-4 membered heterocycle;
R 6A is halogen, CN, OR 6B , SR 6C , S(O) 2 R 6C , C(O)R 6B , unsubstituted C 1-3 alkyl, unsubstituted C 1-3 haloalkyl, or R 6B -substituted or unsubstituted 3-4 membered heterocycle; and
R 6B and R 6C are each independently C 1-3 alkyl or C 1-3 haloalkyl.
5 - 8 . (canceled)
9 . A compound of formula (I):
or a stereoisomer, atropisomer, tautomer, or pharmaceutically acceptable salt thereof,
wherein
X is O or NR 6 ;
m is 1 or 2;
n is 1 or 2;
wherein n and m together make a 6— or 7-membered ring Ring A;
p is 0, 1, or 2;
L 1 is R L i-substituted or unsubstituted C 1-4 alkylene;
R L1 is halogen or unsubstituted C 1-3 alkyl, or wherein two R L1 together form an unsubstituted C3-4 cycloalkyl;
R 2 is R 9 -substituted or unsubstituted 4-10 membered heterocycle comprising one or more heteroatoms selected from N, S, or O;
R 9 is independently halogen, CN, OH, OCF 3 , OCHF 2 , OCH 2 F, R 10 -substituted or unsubstituted C 1-3 alkyl, R 10 -substituted or unsubstituted C 1-3 haloalkyl, unsubstituted C 1-3 alkoxy, R 10 -substituted or unsubstituted C 1-3 alkylidene, or R 10 -substituted or unsubstituted C 3 0.4 cycloalkyl, or R 10 -substituted or unsubstituted 3 or 4-membered heterocycle; or wherein two R 9 together form a R 10 -substituted or unsubstituted C 3-5 cycloalkyl or a R 10 -substituted or unsubstituted C 3-5 heterocycle comprising one or more oxygen atoms; or wherein two R 9 together form a bridge between two carbon atoms of the cycloalkyl or heterocycle, wherein the bridge comprises 1-3 carbons;
each R 10 is independently hydrogen, oxo, CN, halogen, or C 1-3 unsubstituted alkyl;
R 3 is hydrogen, —CN, halogen, unsubstituted C 1-3 alkyl, or unsubstituted cyclopropyl;
each R 4 is independently hydrogen, methyl, or C 1-3 haloalkyl;
R 5 is independently halogen, oxo, unsubstituted C 1-3 alkyl, or unsubstituted C 1-3 haloalkyl;
or wherein two R 5 together form a bridge between two carbon atoms of Ring A, wherein the bridge comprises 1-3 carbons and optionally one heteroatom selected from O and N; or
two R 5 together form a bridge between two carbon atoms of Ring A, wherein the bridge comprises one of O or NR 11 ;
R 11 is hydrogen, C(O)CH 3 , or unsubstituted C 1-3 alkyl;
R 6 is hydrogen, R 6A -substituted or unsubstituted C 1 -6 alkyl, R 6A -substituted or unsubstituted C 1 -s haloalkyl, R 6A -substituted or unsubstituted C 1 -6 alkenyl; R 6A -substituted or unsubstituted C 1-6 alkynyl, or R 6A -substituted or unsubstituted 3-4 membered heterocycle;
R 6A is halogen, CN, OR 6B , SR 6C , S(O) 2 R 6C , C(O)R 6B , unsubstituted C 1-3 alkyl, unsubstituted C 1-3 haloalkyl, or R 6B -substituted or unsubstituted 3-4 membered heterocycle; and
R 6B and R 6C are each independently C 1-3 alkyl or C 1-3 haloalkyl.
10 . A compound of formula (I):
or a stereoisomer, atropisomer, tautomer, or pharmaceutically acceptable salt thereof,
wherein
X is O or NR 6 ;
m is 1 or 2;
n is 1 or 2;
wherein n and m together make a 6— or 7-membered ring Ring A;
p is 0, 1, or 2;
R 1 is R 7A -substituted phenyl or R 7A substituted pyridinyl;
each R 7A is independently halogen, NH 2 , unsubstituted C 1-3 alkyl, or unsubstituted C 1-3 haloalkyl;
L 1 is R L1 -substituted or unsubstituted C 1-4 alkylene;
R L1 is halogen or unsubstituted C 1-3 alkyl, or wherein two R L1 together form an unsubstituted C3.4 cycloalkyl;
R 2 is R 9 -substituted or unsubstituted 4-10 membered heterocycle comprising one or more heteroatoms selected from N, S, or O;
R 9 is independently halogen, CN, OH, OCF 3 , OCHF 2 , OCH 2 F, R 10 -substituted or unsubstituted C 1-3 alkyl, R 10 -substituted or unsubstituted C 1-3 haloalkyl, unsubstituted C 1-3 alkoxy, R 10 -substituted or unsubstituted C 1-3 alkylidene, or R 10 -substituted or unsubstituted C 3 0.4 cycloalkyl, or R 10 -substituted or unsubstituted 3 or 4-membered heterocycle; or wherein two R 9 together form a R 10 -substituted or unsubstituted C 3-5 cycloalkyl or a R 10 -substituted or unsubstituted C 3-5 heterocycle comprising one or more oxygen atoms; or wherein two R 9 together form a bridge between two carbon atoms of the cycloalkyl or heterocycle, wherein the bridge comprises 1-3 carbons;
each R 10 is independently hydrogen, oxo, CN, halogen, or C 1-3 unsubstituted alkyl;
R 3 is hydrogen, —CN, halogen, unsubstituted C 1-3 alkyl, or unsubstituted cyclopropyl;
each R 4 is independently hydrogen, methyl, or C 1-3 haloalkyl;
R 5 is independently halogen, oxo, unsubstituted C 1-3 alkyl, or unsubstituted C 1-3 haloalkyl;
or wherein two R 5 together form a bridge between two carbon atoms of Ring A, wherein the bridge comprises 1-3 carbons and optionally one heteroatom selected from O and N; or
two R 5 together form a bridge between two carbon atoms of Ring A, wherein the bridge comprises one of 0 or NR 11 ;
R 11 is hydrogen, C(O)CH 3 , or unsubstituted C 1-3 alkyl;
R 6 is hydrogen, R 6A -substituted or unsubstituted C 1 -6 alkyl, R 6A -substituted or unsubstituted C 1 -s haloalkyl, R 6A -substituted or unsubstituted C 1-6 alkenyl; R 6A -substituted or unsubstituted C 1-6 alkynyl, or R 6A -substituted or unsubstituted 3-4 membered heterocycle;
R 6A is halogen, CN, OR 6B , SR 6C , S(O) 2 R 6C , C(O)R 6B , unsubstituted C 1-3 alkyl, unsubstituted C 1-3 haloalkyl, or R 6B -substituted or unsubstituted 3-4 membered heterocycle; and
R 6B and R 6C are each independently C 1-3 alkyl or C 1-3 haloalkyl.
11 . A compound of formula (I):
or a stereoisomer, atropisomer, tautomer, or pharmaceutically acceptable salt thereof,
wherein
X is O or NR 6 ;
m is 1 or 2;
n is 1 or 2;
wherein n and m together make a 6— or 7-membered ring Ring A;
p is 0, 1, or 2;
L 1 is R L1 -substituted or unsubstituted C 1-4 alkylene;
R L1 is halogen or unsubstituted C 1-3 alkyl, or wherein two R L1 together form an unsubstituted C3.4 cycloalkyl;
R 2 is R 9 -substituted or unsubstituted 4-10 membered heterocycle comprising one or more heteroatoms selected from N, S, or O;
R 9 is independently halogen, CN, OH, OCF 3 , OCHF 2 , OCH 2 F, R 10 -substituted or unsubstituted C 1-3 alkyl, R 10 -substituted or unsubstituted C 1-3 haloalkyl, unsubstituted C 1-3 alkoxy, R 10 -substituted or unsubstituted C 1-3 alkylidene, or R 10 -substituted or unsubstituted C 3 0.4 cycloalkyl, or R 10 -substituted or unsubstituted 3 or 4-membered heterocycle; or wherein two R 9 together form a R 10 -substituted or unsubstituted C 3-5 cycloalkyl or a R 10 -substituted or unsubstituted C 3-5 heterocycle comprising one or more oxygen atoms; or wherein two R 9 together form a bridge between two carbon atoms of the cycloalkyl or heterocycle, wherein the bridge comprises 1-3 carbons;
each R 10 is independently hydrogen, oxo, CN, halogen, or C 1-3 unsubstituted alkyl;
R 3 is hydrogen, —CN, halogen, unsubstituted C 1-3 alkyl, or unsubstituted cyclopropyl;
each R 4 is independently hydrogen, methyl, or C 1-3 haloalkyl;
R 5 is independently halogen, oxo, unsubstituted C 1-3 alkyl, or unsubstituted C 1-3 haloalkyl;
or wherein two R 5 together form a bridge between two carbon atoms of Ring A, wherein the bridge comprises 1-3 carbons and optionally one heteroatom selected from O and N; or
two R 5 together form a bridge between two carbon atoms of Ring A, wherein the bridge comprises one of O or NR 11 ;
R 11 is hydrogen, C(O)CH 3 , or unsubstituted C 1-3 alkyl;
R 6 is hydrogen, R 6A -substituted or unsubstituted C 1-6 alkyl, R 6A -substituted or unsubstituted C 1 -s haloalkyl, R 6A -substituted or unsubstituted C 1 -6 alkenyl; R 6A -substituted or unsubstituted C 1-6 alkynyl, or R 6A -substituted or unsubstituted 3-4 membered heterocycle;
R 6A is halogen, CN, OR 6B , SR 6C , S(O) 2 R 6C , C(O)R 6B , unsubstituted C 1-3 alkyl, unsubstituted C 1-3 haloalkyl, or R 6B -substituted or unsubstituted 3-4 membered heterocycle; and
R 6B and R 6C are each independently C 1-3 alkyl or C 1-3 haloalkyl.
12 . A compound of formula (I):
or a stereoisomer, atropisomer, tautomer, or pharmaceutically acceptable salt thereof,
wherein
X is O or NR 6 ;
m is 1 or 2;
n is 1 or 2;
wherein n and m together make a 6— or 7-membered ring Ring A;
p is 0, 1, or 2;
R 1 is of formula
each R 7A is independently halogen, CN, NH 2 , N(Me) 2 , R 7B -substituted or unsubstituted C 1-3 alkyl, unsubstituted C 1-3 haloalkyl, or unsubstituted cyclopropyl;
R 7B is CN, oxo, or C 1-3 alkyl;
L 1 is R L i-substituted or unsubstituted C 1-4 alkylene;
R L1 is halogen or unsubstituted C 1-3 alkyl, or wherein two R L1 together form an unsubstituted C3.4 cycloalkyl;
R 2 is R 9 -substituted or unsubstituted 4-10 membered heterocycle comprising one or more heteroatoms selected from N, S, or O;
R 9 is independently halogen, CN, OH, OCF 3 , OCHF 2 , OCH 2 F, R 10 -substituted or unsubstituted C 1-3 alkyl, R 10 -substituted or unsubstituted C 1-3 haloalkyl, unsubstituted C 1-3 alkoxy, R 10 -substituted or unsubstituted C 1-3 alkylidene, or R 10 -substituted or unsubstituted C 3 0.4 cycloalkyl, or R 10 -substituted or unsubstituted 3 or 4-membered heterocycle; or wherein two R 9 together form a R 10 -substituted or unsubstituted C 3-5 cycloalkyl or a R 10 -substituted or unsubstituted C 3-5 heterocycle comprising one or more oxygen atoms; or wherein two R 9 together form a bridge between two carbon atoms of the cycloalkyl or heterocycle, wherein the bridge comprises 1-3 carbons;
each R 10 is independently hydrogen, oxo, CN, halogen, or C 1-3 unsubstituted alkyl;
R 3 is hydrogen, —CN, halogen, unsubstituted C 1-3 alkyl, or unsubstituted cyclopropyl;
each R 4 is independently hydrogen, methyl, or C 1-3 haloalkyl;
R 5 is independently halogen, oxo, unsubstituted C 1-3 alkyl, or unsubstituted C 1-3 haloalkyl;
or wherein two R 5 together form a bridge between two carbon atoms of Ring A, wherein the bridge comprises 1-3 carbons and optionally one heteroatom selected from O and N; or
two R 5 together form a bridge between two carbon atoms of Ring A, wherein the bridge comprises one of O or NR 11 ;
R 11 is hydrogen, C(O)CH 3 , or unsubstituted C 1-3 alkyl;
R 6 is hydrogen, R 6A -substituted or unsubstituted C 1-6 alkyl, R 6A -substituted or unsubstituted C 1-6 haloalkyl, R 6A -substituted or unsubstituted C 1-6 alkenyl; R 6A -substituted or unsubstituted C 1-6 alkynyl, or R 6A -substituted or unsubstituted 3-4 membered heterocycle;
R 6A is halogen, CN, OR 6B , SR 6C , S(O) 2 R 6C , C(O)R 6B , unsubstituted C 1-3 alkyl, unsubstituted C 1-3 haloalkyl, or R 6B -substituted or unsubstituted 3-4 membered heterocycle; and
R 6B and R 6C are each independently C 1-3 alkyl or C 1-3 haloalkyl.
13 . A compound of formula (I):
or a stereoisomer, atropisomer, tautomer, or pharmaceutically acceptable salt thereof,
wherein
X is O or NR 6 ;
m is 1 or 2;
n is 1 or 2;
wherein n and m together make a 6— or 7-membered ring Ring A;
p is 0, 1, or 2;
R 1 is
L 1 is R L1 -substituted or unsubstituted C 1-4 alkylene;
R L1 is halogen or unsubstituted C 1-3 alkyl, or wherein two R L1 together form an unsubstituted C3.4 cycloalkyl;
R 2 is R 9 -substituted or unsubstituted 4-10 membered heterocycle comprising one or more heteroatoms selected from N, S, or O;
R 9 is independently halogen, CN, OH, OCF 3 , OCHF 2 , OCH 2 F, R 10 -substituted or unsubstituted C 1-3 alkyl, R 10 -substituted or unsubstituted C 1-3 haloalkyl, unsubstituted C 1-3 alkoxy, R 10 -substituted or unsubstituted C 1-3 alkylidene, or R 10 -substituted or unsubstituted C 3-4 cycloalkyl, or R 10 -substituted or unsubstituted 3 or 4-membered heterocycle; or wherein two R 9 together form a R 10 -substituted or unsubstituted C 3-5 cycloalkyl or a R 10 -substituted or unsubstituted C 3-5 heterocycle comprising one or more oxygen atoms; or wherein two R 9 together form a bridge between two carbon atoms of the cycloalkyl or heterocycle, wherein the bridge comprises 1-3 carbons;
each R 10 is independently hydrogen, oxo, CN, halogen, or C 1-3 unsubstituted alkyl;
R 3 is hydrogen, —CN, halogen, unsubstituted C 1-3 alkyl, or unsubstituted cyclopropyl;
each R 4 is independently hydrogen, methyl, or C 1-3 haloalkyl;
R 5 is independently halogen, oxo, unsubstituted C 1-3 alkyl, or unsubstituted C 1-3 haloalkyl;
or wherein two R 5 together form a bridge between two carbon atoms of Ring A, wherein the bridge comprises 1-3 carbons and optionally one heteroatom selected from O and N; or
two R 5 together form a bridge between two carbon atoms of Ring A, wherein the bridge comprises one of O or NR 11 ;
R 11 is hydrogen, C(O)CH 3 , or unsubstituted C 1-3 alkyl;
R 6 is hydrogen, R 6A -substituted or unsubstituted C 1 -6 alkyl, R 6A -substituted or unsubstituted C 1 -s haloalkyl, R 6A -substituted or unsubstituted C 1 -6 alkenyl; R 6A -substituted or unsubstituted C 1-6 alkynyl, or R 6A -substituted or unsubstituted 3-4 membered heterocycle;
R 6A is halogen, CN, OR 6B , SR 6C , S(O) 2 R 6C , C(O)R 6B , unsubstituted C 1-3 alkyl, unsubstituted C 1-3 haloalkyl, or R 6B -substituted or unsubstituted 3-4 membered heterocycle; and
R 6B and R 6C are each independently C 1-3 alkyl or C 1-3 haloalkyl.
14 - 23 . (canceled)
24 . The compound or a stereoisomer, atropisomer, tautomer, or pharmaceutically acceptable salt thereof of claim 1 , wherein R 2 is:
or a stereoisomer thereof, wherein
R 9 is independently halogen or R 10 -substituted or unsubstituted C 1-3 alkylidene;
each R 10 is independently hydrogen or halogen; and
r is 1 or 2.
25 . The compound or a stereoisomer, atropisomer, tautomer, or pharmaceutically acceptable salt thereof of claim 1 , wherein R 2 is:
or a stereoisomer thereof.
26 - 39 . (canceled)
40 . The compound or a stereoisomer, atropisomer, tautomer, or pharmaceutically acceptable salt thereof of claim 1 , wherein the compound of formula (I) comprises formula:
or a stereoisomer, atropisomer, tautomer, or pharmaceutically acceptable salt thereof.
41 . (canceled)
42 . A compound selected from compounds 1-291 in Table 1 or a stereoisomer, atropisomer, tautomer, or pharmaceutically acceptable salt thereof.
43 - 51 . (canceled)
52 . A pharmaceutical composition comprising a compound or a stereoisomer, atropisomer, tautomer, or pharmaceutically acceptable salt thereof of claim 1 , and one or more pharmaceutically acceptable excipients.
53 . A method of treating cancer, the method comprising administering an effective amount of a compound or a stereoisomer, atropisomer, tautomer, or pharmaceutically acceptable salt thereof of claim 1 .
54 - 81 . (canceled)
82 . A pharmaceutical composition comprising a compound or a stereoisomer, atropisomer, tautomer, or pharmaceutically acceptable salt thereof of claim 4 , and one or more pharmaceutically acceptable excipients.
83 . A pharmaceutical composition comprising a compound or a stereoisomer, atropisomer, tautomer, or pharmaceutically acceptable salt thereof of claim 9 , and one or more pharmaceutically acceptable excipients.
84 . A pharmaceutical composition comprising a compound or a stereoisomer, atropisomer, tautomer, or pharmaceutically acceptable salt thereof of claim 10 , and one or more pharmaceutically acceptable excipients.
85 . A pharmaceutical composition comprising a compound or a stereoisomer, atropisomer, tautomer, or pharmaceutically acceptable salt thereof of claim 11 , and one or more pharmaceutically acceptable excipients.
86 . A pharmaceutical composition comprising a compound or a stereoisomer, atropisomer, tautomer, or pharmaceutically acceptable salt thereof of claim 12 , and one or more pharmaceutically acceptable excipients.
87 . A pharmaceutical composition comprising a compound or a stereoisomer, atropisomer, tautomer, or pharmaceutically acceptable salt thereof of claim 13 , and one or more pharmaceutically acceptable excipients.
88 . A pharmaceutical composition comprising a compound or a stereoisomer, atropisomer, tautomer, or pharmaceutically acceptable salt thereof of claim 42 , and one or more pharmaceutically acceptable excipients.
89 . A method of treating cancer, the method comprising administering an effective amount of a compound or a stereoisomer, atropisomer, tautomer, or pharmaceutically acceptable salt thereof of claim 4 .
90 . A method of treating cancer, the method comprising administering an effective amount of a compound or a stereoisomer, atropisomer, tautomer, or pharmaceutically acceptable salt thereof of claim 9 .
91 . A method of treating cancer, the method comprising administering an effective amount of a compound or a stereoisomer, atropisomer, tautomer, or pharmaceutically acceptable salt thereof of claim 10 .
92 . A method of treating cancer, the method comprising administering an effective amount of a compound or a stereoisomer, atropisomer, tautomer, or pharmaceutically acceptable salt thereof of claim 11 .
93 . A method of treating cancer, the method comprising administering an effective amount of a compound or a stereoisomer, atropisomer, tautomer, or pharmaceutically acceptable salt thereof of claim 12 .
94 . A method of treating cancer, the method comprising administering an effective amount of a compound or a stereoisomer, atropisomer, tautomer, or pharmaceutically acceptable salt thereof of claim 13 .
95 . A method of treating cancer, the method comprising administering an effective amount of a compound or a stereoisomer, atropisomer, tautomer, or pharmaceutically acceptable salt thereof of claim 42 .Join the waitlist — get patent alerts
Track US2024025919A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.